Editorial Advises Against Routine Hormonal and Vitamin Supplementation in Orthopaedic Surgery
Background
Testosterone replacement therapy (TRT), growth hormone (BPC 157), and vitamin D are often prescribed for various conditions, with potential benefits like improved mood, bone density, and tissue repair. In orthopaedic surgery patients, these supplements are sometimes considered for enhancing functional outcomes, bone healing, and recovery. However, the routine use of these supplements in the perioperative period for orthopaedic surgery patients is a subject of debate, with concerns regarding risks and actual efficacy. This editorial addresses whether these supplements are routinely indicated for orthopaedic surgery patients, particularly in the perioperative setting.
Results
The commentary strongly concluded that despite perceived benefits, testosterone replacement therapy (TRT), growth hormone (specifically BPC 157), and vitamin D supplementation are not routinely indicated for orthopaedic surgery patients. While individual benefits like improved bone mineral density or muscle recovery were acknowledged for specific patient populations, the editorial emphasized that these supplements carry inherent risks that outweigh the benefits for general, routine perioperative application. The author highlighted that patient requests for these supplements, including BPC 157 for optimizing endurance or vitamin D for fracture healing, must be carefully weighed against the absence of a routine indication. The primary finding was a clear recommendation that TRT is not recommended for routine use in the perioperative management of orthopaedic surgery patients due to potential risks and a lack of robust evidence for routine benefit.
Why It Matters
This editorial provides a crucial guideline for orthopaedic surgeons and referring physicians, emphasizing that routine supplementation with testosterone, growth hormone, and vitamin D is generally unwarranted in the perioperative period. This guidance helps prevent unnecessary patient exposure to potential risks associated with these supplements, such as cardiovascular events with TRT or unknown long-term effects of BPC 157. Adherence to this recommendation could streamline patient care, reduce healthcare costs, and prioritize evidence-based interventions. Future research should focus on identifying specific patient subgroups who might genuinely benefit from targeted supplementation, potentially leading to more personalized treatment protocols rather than broad recommendations.